Expression and prognostic significance of SIRT1 in ovarian epithelial tumours

Pathology

Volumn 41, Issue 4, 2009, Pages 366-371

  Jang, Kyu Yun ^a   Kim, Kwan Sik ^a   Hwang, Sung Ho ^a   Kwon, Keun Sang ^a   Kim, Kyung Ryoul ^a   Park, Ho Sung ^a   Park, Byung Hyun ^a   Chung, Myoung Ja ^a   Kang, Myoung Jae ^a   Lee, Dong Geun ^a   Moon, Woo Sung ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Epithelial tumours; Ovary; P53; Prognosis; SIRT1

Indexed keywords

SIRTUIN 1; SIRT1 PROTEIN, HUMAN; SIRTUIN; TUMOR MARKER;

ADULT; ARTICLE; BORDERLINE STATE; CANCER EPIDEMIOLOGY; CANCER STAGING; CONTROLLED STUDY; EPITHELIUM TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY TUMOR; OVERALL SURVIVAL; PREVALENCE; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY; BIOSYNTHESIS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; PATHOLOGY; PROGNOSIS;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SIRTUINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 68849097673     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020902884451     Document Type: Article

References (21)

1. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403: 795-800. (Pubitemid 30111843)
2. Voelter-Mahlknecht S, Mahlknecht U. Cloning, chromosomal characterization and mapping of the NAD-dependent histone deacetylases gene sirtuin 1. Int J Mol Med 2006; 17: 59-67.
3. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004; 73: 417-435
4. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-2015
5. Cohen HY, Lavu S, Bitterman KJ, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004; 13: 627-638
6. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-148
7. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-159
8. Hida Y, Kubo Y, Murao K, Arase S. Strong expression of a longevityrelated protein, SIRT1, in Bowen's disease. Arch Dermatol Res 2007; 299: 103-106
9. Hu.man DM, Grizzle WE, Bamman MM, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007; 67: 6612-6618
10. Kuzmichev A, Margueron R, Vaquero A, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular Differentiation. Proc Natl Acad Sci USA 2005; 102: 1859-1864
11. Lim CS. SIRT1: Tumor promoter or tumor suppressor? Med Hypotheses 2006; 67: 341-344
12. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-116
13. Lim CS. Human SIRT1: A potential biomarker for tumorigenesis? Cell Biol Int 2007; 31: 636-637
14. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005; 123: 437-448
15. Hogg R, Scurry J, Kim SN, Friedlander M, Hacker N. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma. Gynecol Oncol 2007; 106: 44-51.
16. Ozdag H, Teschendor. AE, Ahmed AA, et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006; 7: 90.
17. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kBdependent transcription and cell survival by the SIRT1 deacetylase. Embo J 2004; 23: 2369-2380
18. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic signi.cance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000; 89: 2006-2017
19. Wen WH, Reles A, Runnebaum IB, et al. p53 mutations and expression in ovarian cancers: Correlation with overall survival. Int J Gynecol Pathol 1999; 18: 29-41.
20. Geisler JP, Geisler HE, Wiemann MC, Givens SS, Zhou Z, Miller GA. Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 1997; 66: 435-438
21. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995; 76: 1201-1208